AR089324A1 - Composiciones, metodos y kits para la preparacion de proteinas recombinantes sialiladas - Google Patents

Composiciones, metodos y kits para la preparacion de proteinas recombinantes sialiladas

Info

Publication number
AR089324A1
AR089324A1 ARP120104817A ARP120104817A AR089324A1 AR 089324 A1 AR089324 A1 AR 089324A1 AR P120104817 A ARP120104817 A AR P120104817A AR P120104817 A ARP120104817 A AR P120104817A AR 089324 A1 AR089324 A1 AR 089324A1
Authority
AR
Argentina
Prior art keywords
recombinant proteins
kits
protein
compositions
preparation
Prior art date
Application number
ARP120104817A
Other languages
English (en)
Inventor
Barnett Thomas
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of AR089324A1 publication Critical patent/AR089324A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99004—Beta-galactoside alpha-2,3-sialyltransferase (2.4.99.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Procedimiento para alterar un patrón de sialilación de una o más proteínas recombinantes expresadas en una célula, en el que la célula está modificada genéticamente para expresar recombinantemente una a2,3-sialiltransferasa para sialilar la proteína. Este sistema de expresión incrementa la sialilación de la proteína que se expresa (FVIII - factor anti-hemofílico (AHF) ó factor de von Willebrand (vWF)), en particular la cantidad de un ácido siálico enlazado por a2,3 unido a la proteína. Composición. Célula. Método de tratamiento.
ARP120104817A 2011-12-19 2012-12-19 Composiciones, metodos y kits para la preparacion de proteinas recombinantes sialiladas AR089324A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161577291P 2011-12-19 2011-12-19

Publications (1)

Publication Number Publication Date
AR089324A1 true AR089324A1 (es) 2014-08-13

Family

ID=47681979

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104817A AR089324A1 (es) 2011-12-19 2012-12-19 Composiciones, metodos y kits para la preparacion de proteinas recombinantes sialiladas

Country Status (4)

Country Link
AR (1) AR089324A1 (es)
AU (1) AU2012340501A1 (es)
UY (1) UY34527A (es)
WO (1) WO2013093760A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231183T1 (hr) 2013-02-15 2024-01-05 Bioverativ Therapeutics Inc. Optimizirani gen faktora viii
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
EP3042952A1 (en) 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
US10772936B2 (en) 2015-05-22 2020-09-15 CSL Behring Lengnau AG Methods for preparing modified von Willebrand factor
SG10201910896UA (en) 2015-05-22 2020-01-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
JP7189767B2 (ja) 2015-11-19 2022-12-14 武田薬品工業株式会社 組換えヒトｃ１エステラーゼインヒビター及びその使用
SG10201912498YA (en) 2016-01-07 2020-02-27 CSL Behring Lengnau AG Mutated truncated von willebrand factor
SI3411478T1 (sl) 2016-02-01 2022-10-28 Bioverativ Therapeutics Inc. Optimirani geni dejavnika VIII
AU2017358861B2 (en) 2016-11-11 2022-02-17 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
EP3538134B1 (en) 2016-11-11 2021-12-29 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
WO2018234518A1 (en) 2017-06-22 2018-12-27 CSL Behring Lengnau AG MODULATION OF IMMUNOGENICITY OF FVIII BY VWF TRONQUÉ
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
WO2021081670A1 (en) * 2019-11-01 2021-05-06 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
WO2021094344A1 (en) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US5149637A (en) 1987-04-06 1992-09-22 Scripps Clinic & Research Foundation Recombinant Factor VIIIC fragments
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
KR100482917B1 (ko) 1996-01-23 2005-11-11 퀴아진 지노믹스, 인코포레이티드 핵산분자의서열을결정하는방법및이를위한조성물
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
AT403765B (de) 1996-04-12 1998-05-25 Immuno Ag Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex
US6120460A (en) 1996-09-04 2000-09-19 Abreu; Marcio Marc Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions
NZ501774A (en) 1997-07-22 2002-02-01 Qiagen Genomics Inc Computer method and system for correlating known characteristics of biomolecules to molecular tags with unique molecular weights that are associated with the biomolecule
ATE536417T1 (de) 1999-04-15 2011-12-15 Crucell Holland Bv Herstellung von rekombinanten proteinen in einer menschlichen zelle mit mindestens einem e1 adenovirus protein
US20060099685A1 (en) * 1999-04-15 2006-05-11 Yallop Christopher A Recombinant expression of factor VIII in human cells
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US6664112B2 (en) 2000-06-02 2003-12-16 Blue Heron Biotechnology, Inc. Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides
AU2002357249A1 (en) 2001-12-13 2003-07-09 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
US7642078B2 (en) 2005-12-28 2010-01-05 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
TWI488640B (zh) * 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
US20110086362A1 (en) 2009-10-09 2011-04-14 Massachusetts Institute Of Technology High-Throughput Method for Quantifying Sialylation of Glycoproteins

Also Published As

Publication number Publication date
AU2012340501A1 (en) 2013-07-11
WO2013093760A3 (en) 2013-11-14
UY34527A (es) 2013-07-31
WO2013093760A2 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
AR089324A1 (es) Composiciones, metodos y kits para la preparacion de proteinas recombinantes sialiladas
AR124871A2 (es) Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes
CL2018000238A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
BR112014019901A8 (pt) Proteínas de fator viii recombinante
CO2018005215A2 (es) Construcciones específicas del hígado para expresión del factor viii
ES2600879T3 (es) Preparaciones que contienen el factor de Von Willebrand (FvW) y procedimientos, kits y utilizaciones relacionados con las mismas
CY1122691T1 (el) Πρωτεϊνες δεσμευσης αλβουμινης ορου
PE20130041A1 (es) Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
CL2011003121A1 (es) Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso.
BR112015022558A2 (pt) sequência isolada de ácidos nucleicos do promotor pcs1, construção de expressão ou célula hospedeira recombinante compreendendo a sequência de ácidos nucleicos, cultura celular estável de uma pluralidade das referidas células hospedeiras, método para a produção de uma proteína de interesse e utilização de uma sequência isolada de ácidos nucleicos compreendendo um promotor em um método para a produção de uma proteína de interesse
MY188897A (en) Factor viii compositions and methods of making and using same
BR112015013311A2 (pt) indução de tolerancia e reparação de mutação do fator 8
BRPI0609797B8 (pt) nanocorpos melhorados para o tratamento de desordens mediadas por agregação
IN2014DN09815A (es)
BR112014000466A2 (pt) polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
BR112014012460A2 (pt) proteínas recombinantes e seus usos terapêuticos
BR112016011224A2 (pt) Formulação líquida de uma proteína de fusão que compreende tnfr e região de fc
EA201592022A1 (ru) Расщепляемый тромбином линкер, содержащий xten, и его применение
BR112015012854A2 (pt) método para purificar proteínas terapêuticas
AR091647A1 (es) Purificacion de iduronato-2-sulfatasa
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
BR112013017367A2 (pt) polipeptídeo de alfacarpo, sequência de ácido nucléico, composição farmacêutica e método para a produção de pelo menos um polipeptídeo de alfacorpo
EA202190244A3 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
BR112014008680A2 (pt) proteína de fusão de transferrina-tumstatina e métodos para produzir e usar a mesma

Legal Events

Date Code Title Description
FA Abandonment or withdrawal